An important message for US clinicians. We’re pleased to announce that a final LCD for Urine-based Biomarkers in Patients with Microhematuria (DL40378) has been published, confirming Medicare coverage for Cxbladder Triage Plus and Triage in the evaluation of appropriately counseled intermediate-risk patients. The policy takes effect on December 20, 2026. 

What does this mean for your practice? 

Cxbladder Triage Plus and Triage are the only tests covered within the LCD, and the final policy, once effective, will streamline the use and reimbursement of the tests in eligible Medicare patients.

Pacific Edge Chief Executive Dr Peter Meintjes said: “The final LCD is a significant milestone for Pacific Edge, Medicare patients, urologists, and the broader healthcare system. It provides clear guidance on the eligible hematuria patients for which Triage and Triage Plus should be reimbursed and recognizes the important role that validated, non-invasive urine-based biomarkers can play in helping physicians make better-informed decisions about cystoscopy.”

We’ll be providing more information shortly

We’ll be providing further information shortly ahead of the December 20 effective date. In the meantime, we welcome any questions. Please call us at 1-855-292-5237 or email [email protected].

Review the LCD

The final LCD “Urine-based Biomarkers in Patients with Microhematuria” (L40378) can be accessed via the following link: https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=40378

The final LCA for billing and coding (L60424) can be accessed via the following link:

https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleid=60424

The response to comments article (L60570) can be accessed via the following link:

https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleid=60570